Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee Sells 3,193 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 3,193 shares of Bicycle Therapeutics stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $7.44, for a total value of $23,755.92. Following the completion of the transaction, the chief executive officer owned 480,804 shares of the company's stock, valued at approximately $3,577,181.76. This trade represents a 0.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Kevin Lee also recently made the following trade(s):

• On Wednesday, July 2nd, Kevin Lee sold 2,268 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $7.09, for a total value of $16,080.12.

Bicycle Therapeutics Stock Down 3.5%

Shares of NASDAQ:BCYC traded down $0.26 during midday trading on Monday, hitting $7.17. 220,633 shares of the stock traded hands, compared to its average volume of 396,212. The stock has a market capitalization of $496.52 million, a PE ratio of -2.28 and a beta of 1.41. Bicycle Therapeutics PLC Sponsored ADR has a one year low of $6.10 and a one year high of $28.67. The business's 50 day moving average is $8.07 and its two-hundred day moving average is $10.04.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 790.07% and a negative return on equity of 25.54%. The business had revenue of $9.98 million for the quarter, compared to the consensus estimate of $8.67 million. As a group, sell-side analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new position in shares of Bicycle Therapeutics during the 1st quarter valued at about $214,000. Acadian Asset Management LLC purchased a new stake in Bicycle Therapeutics during the 1st quarter valued at $1,065,000. Woodline Partners LP purchased a new position in shares of Bicycle Therapeutics during the 1st quarter worth about $3,088,000. Millennium Management LLC grew its stake in shares of Bicycle Therapeutics by 156.5% during the first quarter. Millennium Management LLC now owns 453,428 shares of the company's stock valued at $3,850,000 after buying an additional 276,671 shares during the last quarter. Finally, Armistice Capital LLC increased its stake in Bicycle Therapeutics by 21.7% in the first quarter. Armistice Capital LLC now owns 2,672,000 shares of the company's stock worth $22,685,000 after purchasing an additional 476,000 shares during the period. Institutional investors own 86.15% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BCYC. Morgan Stanley set a $17.00 target price on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a research report on Monday, May 5th. JMP Securities lowered their price target on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price target on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Royal Bank Of Canada reduced their price objective on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Barclays dropped their target price on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $25.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.